What's Happening?
Precision BioSciences has announced significant clinical data from its ELIMINATE-B study, presented at the European Association for the Study of the Liver Congress 2026. The study focuses on PBGENE-HBV, a gene editing therapy aimed at treating chronic
hepatitis B. The data reveals that PBGENE-HBV can eliminate and inactivate cccDNA in liver biopsies, marking a first in the field. This development is seen as a potential turning point in hepatitis B treatment, moving from lifelong virus suppression to a finite cure. The study involved 16 patients across five cohorts, showing a 1-log reduction in cccDNA transcripts and a 100% pgRNA loss in patients with detectable levels at baseline. The therapy has demonstrated a manageable safety profile, with no dose-limiting toxicities observed.
Why It's Important?
The findings from the ELIMINATE-B study could revolutionize the treatment of chronic hepatitis B, a condition affecting millions worldwide. By directly targeting and eliminating cccDNA, PBGENE-HBV offers a potential cure rather than just managing symptoms. This aligns with FDA guidance on the desired endpoint for hepatitis B treatments. The success of this therapy could lead to significant advancements in gene editing technologies and their application in treating other viral infections. For patients, this could mean a shift from lifelong medication to a finite treatment plan, improving quality of life and reducing healthcare costs.
What's Next?
Precision BioSciences plans to expand the trial to include more patients and gather additional biopsy data to support the therapy's efficacy. The company is also working on optimizing the dosing schedule for the next phase of the trial. An investor webcast is scheduled to discuss these findings and future plans. The ongoing research and development could lead to regulatory approval and commercialization of PBGENE-HBV, potentially setting a new standard in hepatitis B treatment.
